Multiple Manufacturers

FASLODEX

Manufacturer:

Multiple Manufacturers

Faslodex HCPCS:

J9395

HCPCS Code Descriptor:

Injection, fulvestrant, 25 mg

Category:

J Code

Faslodex NDCs:

00310-0720-10, 00781-3492-12, 68001-0484-85, 72603-0105-02, 16714-0070-02, 67457-0311-05, 70860-0211-74, 70121-1463-02, 00781-3079-12, 68462-0317-32, 70700-0284-98, 62332-0650-10, 70710-1688-08, 68001-0522-85, 16729-0436-30, 00143-9022-02, 55150-0394-02, 25021-0462-74, 00781-9055-12, 43598-0262-02, 71288-0555-86

Primary Type:

Oncology

Generic/Specialty Status:

Multi-Source

Route of Administration:

Intramuscular

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

00781-3492-12, 72603-0105-02, 67457-0311-05, 70860-0211-74, 00781-3079-12, 25021-0462-74

About Faslodex:

FASLODEX is an Oncology drug manufactured by Astrazeneca and administered via the Intramuscular route of administration. The J Code: J9395 is aligned to the drug FASLODEX.

ACCESS PRICING AND MORE BY REGISTERING

J9395 Added Date:

January 1, 2004

J9395 Effective Date:

January 1, 2004

J9395 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Faslodex billing and coding information.
Faslodex patient assistance information can be found through The AZ&Me Prescription Savings Program at the URL: https://www.azandmeapp.com/prescriptionsavings/
FASLODEX prescribing information can be found at the link below. Please reach out to us if you believe this information to be innacurate or out of date.
Our team has not yet identified a source of side effects information for FASLODEX. Please check back in a few weeks.